Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 18/20 | 0.52 |
| ▸ | MAPK11 | Q15759 | 9/20 | 0.52 |
| ▸ | MAPK13 | O15264 | 8/20 | 0.52 |
| ▸ | MAPK12 | P53778 | 8/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.39 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4060643 | 0.89 | MAPK14 (0.49) | MAPK14MAPK11MAPK13MAPK12KCNH2 | |
| SCHEMBL4069015 | 0.83 | MAPK14 (0.52) | MAPK14MAPK11MAPK13MAPK12KCNH2 | |
| SCHEMBL4064478 | 0.77 | MAPK14 (0.47) | MAPK14MAPK11MAPK13MAPK12 | |
| SCHEMBL13702959 | 0.77 | MAPK14 (0.47) | MAPK14MAPK11MAPK13MAPK12 | |
| SCHEMBL4299635 | 0.76 | MAPK14 (0.50) | MAPK14MAPK11MAPK13MAPK12KCNH2 | |
| SCHEMBL27630502 | 0.75 | MAPK14 (0.45) | MAPK14MAPK11MAPK13MAPK12KCNH2 | |
| SCHEMBL17950058 | 0.71 | MAPK14 (0.41) | MAPK14MAPK11MAPK13MAPK12KCNH2 | |
| SCHEMBL17950040 | 0.70 | KDM4E (0.47) | MAPK14MAPK11MAPK13MAPK12 | |
| SCHEMBL6864369 | 0.69 | MAPK14 (0.71) | MAPK14MAPK11MAPK13MAPK12KCNH2 | |
| SCHEMBL17950059 | 0.68 | MAPK14 (0.43) | MAPK14MAPK11MAPK13MAPK12NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1596860-A4 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2009-05-27 | — | — | EP | claimed |
| US-20060211727-A1 | Novel compounds | GLAXOSMITHKLINE LLC | 2006-09-21 | — | — | US | claimed |
| EP-1596860-A2 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-11-23 | — | — | EP | claimed |
| WO-2004073628-A2 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-09-02 | — | — | WO | claimed |
| US-20090239897-A1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION | 2009-09-24 | — | — | US | disclosed |
| US-20090239897-A1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION | 2009-09-24 | — | — | US | disclosed |
| US-20090239897-A1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION | 2009-09-24 | — | — | US | disclosed |
| US-7550480-B2 | Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2009-06-23 | — | — | US | disclosed |
| US-7550480-B2 | Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2009-06-23 | — | — | US | disclosed |
| US-7550480-B2 | Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2009-06-23 | — | — | US | disclosed |
| EP-1596860-A4 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2009-05-27 | — | — | EP | disclosed |
| US-20060211727-A1 | Novel compounds | GLAXOSMITHKLINE LLC | 2006-09-21 | — | — | US | disclosed |
| EP-1596860-A2 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-11-23 | — | — | EP | disclosed |
| WO-2004073628-A2 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239897-A1 | NOVEL COMPOUNDS | MAPKAPK2, CREBBP, MAPK1 | MAPK14 32/4885MAPK11 66/4885MAPK13 60/4885 |
| US-20060211727-A1 | Novel compounds | MAPKAPK2, CREBBP, MAPK1 | MAPK14 32/4885MAPK11 66/4885MAPK13 60/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.